 TORONTO, ON ACCESSWIRE June 18, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an independent Data and Safety Monitoring Board DSMB has completed an interim review of the companys COVID-19 drug candidate, and based on blinded comparative data, has recommended that the companys international study continue as planned. The safety monitoring board, composed of independent subject matter experts, conducted a pre-planned interim review of the first patient cohort participating in Edesas Phase 23 clinical study evaluating the companys EB05 drug candidate as a single-dose treatment for hospitalized COVID-19 patients. 